The objective of this review is to collect data regarding the preclinical and clinical activity of new-generation drugs across different BC intrinsic subtypes caused by germline PVs in BRCA1/2 genes, with the aim of helping to optimize patient and treatment selection while trying to understand the molecular pathways that lead to greater or lesser therapy response. The gene discussed is BRCA1; the disease is breast cancer.